Untreated US Workplace Mental Health Costs $3.7 Trillion

Annual U.S. spending on mental health treatment is only 1.1% of what companies lose.

January 16, 2023

According to a recent study by the health and wellness publisher HealthCanal, untreated workplace mental illness costs U.S. businesses US$3.7 trillion dollars each year, even though annual spending on mental health treatment in the United States is just 1.1% of that figure ($43 billion).

Lost working time alone costs companies $1 trillion, while treatment and employee turnover due to mental illness cost the remaining $2.7 trillion.

In the study, California led as the top state with companies bearing the greatest economic burden at more than $452 billion. However, the Golden State also ranked as the one that receives the highest returns from investing in workplace mental health treatment—$27 billion.

Washington D.C ranked as the worst U.S. location in failing to meet the needs of workplace mental help, closely followed by the state of Alabama. But the study found that no state in the Union invests enough in mental health care to completely offset the needs of workers who have mental illnesses.

Latest Articles

Improve Restroom Hygiene by Reducing Urinal Splashback
August 25, 2025 Klaus Reichardt

Improve Restroom Hygiene by Reducing Urinal Splashback

August 21, 2025 Jeff Cross

Busyness vs. Business in the Age of AI

August 19, 2025 Jeff Cross

For BSCs, Big or Small, Strategy Decides It All

Sponsored Articles

Everyday Champions: Facility Professionals Recognition Program
August 18, 2025

Everyday Champions: Facility Professionals Recognition Program

August 6, 2025

Your Public Restroom Could Be Costing You: Why Inclusive Hygiene Matters

July 29, 2025 Sponsored by OPTISOLVE

Beyond Automation: How SAVI 360 Supports Frontline Cleaning Teams

Recent News

Caution Prairie Dogs Have Plague

California Resident Tests Positive for Plague

People Say Visible Stains and Odor Removal Top Reasons for Carpet Cleaning

Pediatricians Release Updated Recommendations for COVID-19 Vaccines